Single-station skip-N2 disease: good prognosis in resected non-small-cell lung cancer (long-term results in skip-N2 disease)

被引:18
|
作者
Yazgan, Serkan [1 ]
Ucvet, Ahmet [1 ]
Gursoy, Soner [1 ]
Samancilar, Ozgur [1 ]
Yagci, Tarik [1 ]
机构
[1] Univ Hlth Sci, Dr Suat Seren Chest Dis & Surg, Med Practice & Res Ctr, Dept Thorac Surg, Izmir, Turkey
关键词
Non-small-cell lung cancer; Lymph node; Metastasis; MEDIASTINAL LYMPH-NODES; NEOADJUVANT CHEMOTHERAPY; PRIMARY TUMOR; N2; DISEASE; STAGE; METASTASIS; SURVIVAL; SURGERY; CARCINOMAS;
D O I
10.1093/icvts/ivy244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Pathological N2 (pN2) involvement has a negative impact on prognosis in patients operated on due to non-small-cell lung cancer (NSCLC). pN2 disease may cause skip (pN0N2) or non-skip (pN1N2) metastases with pathological N1 (pN1) involvement. The effect of pN2 subgroups on prognosis is still controversial. We analysed the effect of pN1 disease and single-station pN2 disease subgroups on survival outcomes. METHODS The medical records of patients who underwent anatomical lung resection due to NSCLC at a single centre between January 2007 and January 2017 were prospectively collected and retrospectively analysed. Operative mortality, sublobar resection, Stage IV disease, incomplete resection and carcinoid tumour were considered exclusion criteria. After histopathological examination, the prognosis of patients with pN1, pN0N2 and pN1N2 was compared statistically. Univariable and multivariable analyses were made to define independent risk factors for overall survival rates. RESULTS The mean follow-up time for 358 patients with 228 pN1 disease (63.7%), 59 pN0N2 disease (16.5%) and 71 pN1N2 disease (19.8%) was 40.430.4months. Median and 5-year overall survival rates for pN1, pN0N2 and pN1N2 diseases were 73.6months [95% confidence interval (CI) 55.5-91.7] and 54.1%, 60.3months (95% CI 26.8-93.8) and 51.2%, 20.8months (95% CI 16.1-25.5) and 21.5%, respectively. The survival CIs of pN1 and pN0N2 diseases were similar, and the survival rates of these 2 groups were significantly better than those with pN1N2 (P<0.001, P=0.001, respectively). In multivariable analysis, patients over the age of 60 [hazard ratio (HR) 2.13, P<0.001], patients not receiving adjuvant therapy (HR 1.52, P=0.01) and patients with pN1N2 disease (HR 2.91, P<0.001) had a poor prognosis. CONCLUSIONS Advanced age, not receiving adjuvant therapy and having pN1N2 disease are negative prognostic factors in patients with nodal involvement who underwent curative resection due to NSCLC. The overall survival and recurrence-free survival rates of pN1 disease and single-station pN0N2 disease are similar, and they have significantly better survival rates than pN1N2 disease. Based on these results, surgical treatment may be considered an appropriate choice in patients with histopathologically diagnosed single-station skip-N2 disease.
引用
收藏
页码:247 / 252
页数:6
相关论文
共 50 条
  • [21] Predictors for Pathological N1 and N2 Disease in Clinical N1 Non-Small-Cell Lung Cancer
    Fukui, Takayuki
    Okasaka, Toshiki
    Kawaguchi, Koji
    Fukumoto, Koichi
    Nakamura, Shota
    Hakiri, Shuhei
    Ozeki, Naoki
    Yokoi, Kohei
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S589 - S589
  • [22] Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients
    Li, Xin
    Li, Xiaofei
    Fu, Xiangning
    Liu, Lunxu
    Liu, Yang
    Zhao, Heng
    Li, Yin
    Hu, Jian
    Xu, Lin
    Liu, Deruo
    Yang, Haiying
    Zhang, Xun
    EJSO, 2020, 46 (10): : 1874 - 1881
  • [23] Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART Comment
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk K. M.
    LANCET ONCOLOGY, 2022, 23 (01) : 8 - 9
  • [24] Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer
    Higgins, Kristin A.
    Chino, Junzo P.
    Ready, Neal
    Onaitis, Mark W.
    Berry, Mark F.
    D'Amico, Thomas A.
    Kelsey, Chris R.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2011, 142 (05) : 1175 - 1179
  • [25] Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non-small-cell lung carcinoma
    Benoit, L.
    Anusca, A.
    Ortega-Deballon, P.
    Cheynel, N.
    Bernard, A.
    Favre, J. P.
    EJSO, 2006, 32 (05): : 583 - 587
  • [26] Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer
    Kawasaki, Keishi
    Sato, Yasunori
    Suzuki, Yoshio
    Saito, Haruhisa
    Nomura, Yukihiro
    Yoshida, Yukihiro
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 21 (03) : 217 - 222
  • [27] Surgery following neoadjuvant chemotherapy for non-small-cell lung cancer patients with unexpected persistent pathological N2 disease
    Hu, Xue-Fei
    Duan, Liang
    Jiang, Ge-Ning
    Chen, Chang
    Fei, Ke
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (02) : 261 - 267
  • [28] Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non-Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and a Single-Station Involvement
    Okami, Jiro
    Nishiyama, Kinji
    Fujiwara, Ayako
    Konishi, Koji
    Kanou, Takashi
    Tokunaga, Toshiteru
    Teshima, Teruki
    Higashiyama, Masahiko
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (11) : 1417 - 1424
  • [29] The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer
    Thomas, Daniel C.
    Arnold, Brian N.
    Rosen, Joshua E.
    Salazar, Michelle C.
    Detterbeck, Frank C.
    Blasberg, Justin D.
    Boffa, Daniel J.
    Kim, Anthony W.
    WORLD JOURNAL OF SURGERY, 2018, 42 (01) : 161 - 171
  • [30] Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer
    Hiroaki Komatsu
    Shinjiro Mizuguchi
    Nobuhiro Izumi
    Kyukwang Chung
    Shoji Hanada
    Hidetoshi Inoue
    Shigefumi Suehiro
    Noritoshi Nishiyama
    World Journal of Surgical Oncology, 11